Japan caps semaglutide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger in 2025
Page 10 of 10 of this archive, newest first.
Side effects, cost, supply, target: four reasons with four trajectories
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
Sending the same vial twice, under two names
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
South Africa caps tirzepatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Japan declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The supply gap as a clinical event
Why the reason for stopping changes what happens afterwards.
France caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Three services, one lot, and a spread of two and a half points
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Randomised withdrawal is the cleanest design in this field and the least discussed
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.